Greetje J Tack

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. Tack G, van Asseldonk D, Van Wanrooij R, van Bodegraven A, Mulder C. Tioguanine in the treatment of refractory coeliac disease--a single centre experience. Aliment Pharmacol Ther. 2012;36:274-81 pubmed publisher
    ..Tioguanine appears to be a convenient drug for the treatment of refractory coeliac disease type I based on higher histological and similar clinical response rates as compared with historical conventional therapies. ..
  2. Tack G, van Kelckhoven B, Kuyvenhoven J. An unusual cause of duodenal obstruction in adults. Arab J Gastroenterol. 2015;16:63-5 pubmed publisher
    ..In addition, particularly radiologic findings are supportive in diagnosing malrotation. ..
  3. Tack G, van Wanrooij R, von Blomberg B, Amini H, Coupé V, Bonnet P, et al. Serum parameters in the spectrum of coeliac disease: beyond standard antibody testing--a cohort study. BMC Gastroenterol. 2012;12:159 pubmed publisher
    ..A series of novel serum parameters reveal distinctive immunological characteristics of RCDII and EATL in comparison to uncomplicated CD and RCDI. ..
  4. Tack G, Verbeek W, Al Toma A, Kuik D, Schreurs M, Visser O, et al. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol. 2011;17:506-13 pubmed publisher
    ..Progression into EATL was reported in 16%, all of these patients died. Treatment of RCD II with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL. ..